SCI时时刷

search
+
Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity
Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity
The mitochondria-targeted antioxidants (MTAs) are known to offer protection against mitochondrial oxidative stress. The re...
Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
For patients with severe renal impairment (CrCl ≤ 30 ml/min) or end-stage renal disease (ESRD),...
A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study
A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study
There is no consensus on the safety and effectiveness of adjuvant chemotherapy for patients with stage III colorectal canc...
Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients
Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients
Dabrafenib and trametinib are currently administered at fixed doses, at which interpatient variability in exposure is high...
Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study
Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study
Hydration before starting high-dose methotrexate (HD-MTX) ensures good renal perfusion and alkaline urinary pH. The durati...
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy
Despite the beneficial effects of chemotherapy, therapy-induced senescence (TIS) manifests itself as an undesirable byprod...
Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma
Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma
This manuscript reports on the occurrence of early and frequent erythrocytosis in advanced hepatocellular carcinoma (HCC) ...
Correction to: A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
Correction to: A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which ...
Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer
Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer
Tumor metastasis is promoted by an immunosuppressive environment. Lactoferrin (Lf) is known to regulate immunological acti...
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
Galectin-3, a β-galactoside-binding lectin, plays a key role in several cellular pathways involved in chronic inflamm...
Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways
Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways
Gastric cancer (GC) is a life-threatening malignant tumor with high incidence rate. Despite great progress, there are stil...
Assay performance and stability of uracil and dihydrouracil in clinical practice
Assay performance and stability of uracil and dihydrouracil in clinical practice
Measurement of endogenous uracil (U) is increasingly being used as a dose-individualization method in the treatment of can...
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia
Gemtuzumab ozogamicin (GO) is indicated for treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). The QT in...
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
To determine the systemic exposure to cisplatin and paclitaxel after adjuvant intraperitoneal administration in patients w...
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Entrectinib is a central nervous system-active potent inhibitor of tropomyosin receptor kinase (TRK), with anti-t...
Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report
Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report
Fluoropyrimidines (FPs) form still nowadays the backbone of chemotherapic schemes in colorectal cancer (CRC). Inter-patien...
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors
Everolimus (EVE) and sorafenib (SOR) combination was associated with synergistic activity in preclinical models. However, ...
Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients
Determination of 5-azacitidine in human plasma by LC–MS/MS: application to pharmacokinetics pilot study in MDS/AML patients
Azacitidine (Vidaza®, AZA) is a mainstay for treating acute myeloid leukemia (AML) in patients unfit for standard ind...
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies
Belinostat is an intravenous histone deacetylase inhibitor with approval for T-cell lymphomas. Adavosertib is a first in c...
Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions
Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions
This study aimed at characterizing indotecan population pharmacokinetics and explore the indotecan–neutropenia relat...
A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C
Guanylyl cyclase C (GCC) is highly expressed in several gastrointestinal malignancies and preclinical studies suggest that...
PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials
PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials
Chemotherapy is the standard treatment for triple-negative breast cancer (TNBC). Whether the addition of PARP inhibitors i...
Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance
Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance
Natural products, also referred to as dietary supplements, complementary and alternative medicines, and health or food sup...
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo
Glioblastoma (GBM) has a very poor prognosis despite current treatment. We previously found cytotoxic synergy between the ...
A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions
A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions
Colorectal cancer (CRC) is the second most common cause of cancer death worldwide. Trifluridine (FTD) remained at higher c...
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
In the phase 3 CheckMate 9ER trial, intravenous nivolumab (240 mg every 2 weeks) plus oral cabozantinib ...
The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer
The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer
Breast cancer treatment is associated with adverse effects, which may delay return-to-work. Single nucleotide polymorphism...
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration
SHC014748M is a potent, novel selective PI3Kδ isoform inhibitor and is proposed for the treatment of non-Hodgkin lymp...
Value of whole-body dynamic 18F-FMISO PET/CT Patlak multi-parameter imaging for evaluating the early radiosensitizing effect of oleanolic acid on C6 rat gliomas
Value of whole-body dynamic 18F-FMISO PET/CT Patlak multi-parameter imaging for evaluating the early radiosensitizing effect of oleanolic acid on C6 rat gliomas
The purpose of this study was to investigate the value of tumour-to-muscle (T/M) ratios and Patlak Ki images extracted fro...
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions
The optimal dose regimen of ruxolitinib (RUX) in children with hemophagocytic lymphohistiocytosis (HLH) remains to be dete...
阅读更多
format_indent_increase